DUBAI—Before the Iran war, 40,000 shipping containers a day moved through Jebel Ali port, a sprawling complex of deep-water piers and warehouses that powered this city-state’s rise from backwater to ...

Dusk Group is expanding its development pipeline horizons again with plans filed for an eight-storey residential tower a block back from the Redcliffe beachfront. The proposal would deliver 70 ...

The Federal Reserve's latest "dot plot," outlining policymakers' interest rate projections, revealed a sharp shift in central bankers' expectations. Not only are rate cuts almost surely off the table ...

Adaptive Biotechnologies is planning to separate its drug discovery and diagnostics businesses, outlining its intent to evaluate “strategic and structural alternatives” for the medicine wing of the ...

LOS ANGELES (KABC) -- Two men from Riverside County were arrested in connection with an alleged plot targeting President Donald Trump's UFC cage-fighting show at the White House this past weekend, ...

The Virginia man convicted of killing his wife and another man to hide his affair with the family’s Brazilian au pair will spend the rest of his days behind bars after he was sentenced Friday to life ...

Sink, Arbery and Murai all serve as executive producers alongside Steven Prinz and Rachel Jacobs for Borderless Pictures; Michael Costigan and Jason Bateman for Aggregate Films; Eugenides; and Carver ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. The ...

Editor's note: This story has been corrected to reflect that the layoffs at AbbVie’s Irvine site are within the company’s eye care business, not within its Allergan Aesthetics unit as previously ...

Earnings call British Land delivered underlying profit growth of 5% and underlying EPS up 1% YoY, with strong like-for-like net rent growth of 6% and a record year for leasing activity. Management ...

With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in particular—the Tokyo-based drugmaker is following in the footsteps of several of its peers ...